Leveraging Communal Goals To Build A Sustainable Future For Pharma Manufacturing

By William Powers, Senior Director of Business Development

Across industries, the imperative to reduce carbon emissions to help negate the effects of climate change is top of mind, and the pharmaceutical industry is no exception. CDMOs and suppliers alike are facing a challenging imperative: reduce the carbon footprint while maintaining the highest standards of quality and efficiency to ensure program success and patient well-being. As global warming continues to reap devastating effects, including rapidly changing climates, threatened wildlife, destroyed habitats, and depleted natural resources, it is critical to develop more sustainable processes.

In response to this growing crisis, CEOs from seven of the world’s largest pharma companies authored the Open Letter on Supplier Targets from Members of the Sustainable Markets Initiative Health Systems Task Force, which outlines eight sustainability targets for CDMOs to meet in the coming decade. These targets include the reduction of waste, the switch to 80% renewable power by 2030, and the decision to disclose all Scope 1, 2, and 3 emissions. Download the full article to explore how CDMOs are working to reach these targets to contribute to a more sustainable pharmaceutical manufacturing landscape.